Nurix Therapeutics, Inc. $NRIX Stock Holdings Decreased by Braidwell LP

Braidwell LP lessened its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 26.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,286,769 shares of the company’s stock after selling 463,997 shares during the quarter. Braidwell LP’s holdings in Nurix Therapeutics were worth $31,217,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Nurix Therapeutics by 11.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock valued at $593,000 after buying an additional 5,286 shares during the last quarter. Millennium Management LLC lifted its holdings in Nurix Therapeutics by 106.2% during the 1st quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock worth $10,388,000 after buying an additional 450,262 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Nurix Therapeutics by 9.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock worth $6,029,000 after buying an additional 44,002 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Nurix Therapeutics by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock worth $1,895,000 after acquiring an additional 12,817 shares in the last quarter. Finally, Creative Planning acquired a new position in shares of Nurix Therapeutics in the 2nd quarter worth approximately $187,000.

Nurix Therapeutics Trading Down 0.8%

Shares of Nurix Therapeutics stock opened at $25.82 on Thursday. The business’s 50 day simple moving average is $24.79 and its 200-day simple moving average is $19.21. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of -7.48 and a beta of 1.80. Nurix Therapeutics, Inc. has a twelve month low of $8.19 and a twelve month high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The company had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NRIX. Royal Bank Of Canada upped their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Wells Fargo & Company downgraded shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and decreased their price objective for the stock from $28.00 to $25.00 in a report on Monday, June 8th. Jefferies Financial Group boosted their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Wall Street Zen raised shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Truist Financial raised their price target on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.21.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 1,452 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $25.47, for a total value of $36,982.44. Following the sale, the insider directly owned 117,227 shares in the company, valued at approximately $2,985,771.69. This trade represents a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 4,761 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total transaction of $115,977.96. Following the transaction, the chief financial officer directly owned 40,166 shares of the company’s stock, valued at approximately $978,443.76. This trade represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 26,766 shares of company stock worth $626,343 over the last ninety days. 6.70% of the stock is owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.